CoChat

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Open access
Rugo, H.S., Diéras, V., Gelmon, K.A., Finn, R.S., Slamon, D.J., Martin, M., Neven, P., Shparyk, Y., Mori, A., Lu, D.R., Bhattacharyya, H., Bartlett, C.H.u.a.n.g., Iyer, S., Johnston, S., Ettl, J., Harbeck, N. · 2018 · Annals of Oncology
Cited by 153

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background: Patient-reported outcomes are integral in benefit-risk assessments of new treatment regimens. The PALOMA-2 study provides the largest body of evidence for patient-reported health-related quality of life (QOL) for patients with metastatic breast cancer (MBC) receiving first-line endocrine-based therapy (palbociclib plus letrozole and letrozole alone). Patients and methods: Treatment-naïve postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) MBC were randomized 2 : 1 to palbociclib plus letrozole (n = 444) or placebo plus letrozole (n = 222). Patient-reported outcomes were assessed at baseline, day 1 of cycles 2 and 3, and day 1 of every other cycle from cycle 5 using the Functional Assessment of Cancer Therapy (FACT)-Breast and EuroQOL 5 dimensions (EQ-5D) questionnaires. Results: As of 26 February 2016, the median duration of follow-up was 23 months. Baseline scores were comparable between the two treatment arms. No significant between-arm differences were observed in change from baseline in FACT-Breast Total, FACT-General Total, or EQ-5D scores. Significantly greater improvement in pain scores was observed in the palbociclib plus letrozole arm (-0.256 versus -0.098; P = 0.0183). In both arms, deterioration of FACT-Breast Total score was significantly delayed in patients without progression versus those with progression and patients with partial or complete response versus those without. No significant difference was observed in FACT-Breast and EQ-5D index scores in patients with and without neutropenia. Conclusions: Overall, women with MBC receiving first-line endocrine therapy have a good QOL. The addition of palbociclib to letrozole maintains health-related QOL and improves pain scores in treatment-naïve postmenopausal patients with ER+/HER2- MBC compared with letrozole alone. Significantly greater delay in deterioration of health-related QOL was observed in patients without progression versus those who progressed and in patients with an objective response versus non-responders. ClinicalTrials.gov: NCT01740427 (https://clinicaltrials.gov/ct2/show/NCT01740427).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdy012

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 4

  1. Miles, 2002, Combination versus sequential single-agent therapy in metastatic breast cancer, Oncologist, 7, 13, 10.1634/theoncologist.2002-0013 · DOI · Paper page
  2. Zhou, 2009, Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment, Breast Cancer Res Treat, 117, 577, 10.1007/s10549-009-0310-8 · DOI
  3. Harbeck, 2016, Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial, Ann Oncol, 27, 1047, 10.1093/annonc/mdw139 · DOI · Paper page
  4. Campone, 2013, Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy, Curr Med Res Opin, 29, 1463, 10.1185/03007995.2013.836078 · DOI

Cited by

See all 153

Metadata

Authors
Rugo, H. S., Diéras, V., Gelmon, K. A., Finn, R. S., Slamon, D. J., Martin, M., Neven, P., Shparyk, Y., Mori, A., Lu, D. R., Bhattacharyya, H., Bartlett, C. H. U. A. N. G., Iyer, S., Johnston, S., Ettl, J., & Harbeck, N.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2018-04
Volume
29
Issue
4
Pages
888-894
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2791840917
Cited by
153
References
7
FWCI
12.51
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. https://app.cochat.ai/papers/10.1093/annonc/mdy012
The paper
Rugo, H. S., Diéras, V., Gelmon, K. A., Finn, R. S., Slamon, D. J., Martin, M., Neven, P., Shparyk, Y., Mori, A., Lu, D. R., Bhattacharyya, H., Bartlett, C. H. U. A. N. G., Iyer, S., Johnston, S., Ettl, J., & Harbeck, N. (2018). Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial. Annals of Oncology. https://doi.org/10.1093/annonc/mdy012

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.